|
Pipeline
DNAPRINT® PRODUCTS PIPELINE
Click image to enlarge 
BACK TO TOP
PT-401 EPO Dimer
PT-401 is a dimerized (double) and genetically modified form of the popular drug Erythropoietin (EPO), used to treat a condition called anemia. Anemia is a condition of low red blood cell count. Chronic anemia can be caused by many medical conditions such as infectious disease, liver disease, concomitant drug use, autoimmune disease, renal (kidney) disease and cancer chemotherapy. The incidence of chronic anemia has been estimated as high as 8% in the developed world and higher in the undeveloped world. The worldwide market for EPO exceeds $10 billion, and the EPO market is growing at an average annual rate of 21%. Research shows that PT-401 is more potent and longer acting drug than EPO. DNAPrint® is developing the drug as a Theranostic product, with a genomic test for assessing patient compatibility prior to administration.
April 05, 2005 DNAPrint® Genomics Obtains Exclusive License From Beth Israel Deaconess Medical Center, Harvard Affiliate, to Develop New Anemia Drug
BACK TO TOP
AncestryByDNA™ 2.5
ABD2.5 is used to measure an individual’s proportional sub-Saharan African, European, East Asian and Native American ancestry and is the first test of its type ever developed. The technology powering Ancestrybydna 2.5 was initially developed by DNAPrint™ to improve the drug development process and improve clinical trial outcomes.
Ancestrybydna 2.5 website
BACK TO TOP
EURO-DNA™ 1.0
EURO-DNA 1.0 is used to measure proportional Northern European (NOR), Southeast European (MED), Middle Eastern (MIDDEAS) and South Asian ancestry for individuals that are primarily of European ancestry. It is the first test ever developed for measuring within-continental ancestry admixture.
August 27, 2004 DNAPRINT™ LAUNCHES "EURO-DNA 1.0"
BACK TO TOP
EURO-DNA™ 2.0
EURO-DNA 2.0 is used to measure proportional basic continental European ancestry: Southeastern Europe (SEE - Armenian, Jewish, Italian and Greek), Iberian (IB -Spanish, Portuguese), Basque (BAS - Spanish/French Pyrenees border), Continental European (CE - German, Irish, English, Netherlands, French, Swiss and some Italian) and North Eastern European (NEE - Polish, Baltic, Swedish, Norwegian, Finnish, Russian) ancestry. The EuroDNA™ 2.0 test is by far the most advanced genetic ancestry test yet to be offered to the public, bar none. It is based on recently published scientific work using DNA chips to compare populations from around the world. The reference for this test is: Bauchet M, McEvoy B, Pearson L, Quillen E, Sarkisian T, Hovhannesyan K, Deka R, Bradley D, Shriver M. 2007. Measuring European population stratification with microarray genotype data. American Journal of Human Genetics 80(5): 948-956.
June 18, 2007 DNAPRINT™ LAUNCHES "EURO-DNA™ 2.0"
BACK TO TOP
RETINOME
Retinome is a genetic test that allows an individual’s iris color to be predicted from their DNA. It is the first genetics test yet developed for predicting a complex human trait from DNA and is used by forensics investigators who desire to paint a “physical portrait” for a donor of crime-scene DNA. August 17, 2004 DNAPrint™ Announces the release of RETINOME™ for the Forensic Market: Eye Color Prediction from Crime Scene DNA
BACK TO TOP
OVANOME
Ovanome is a genetic test for predicting an ovarian cancer patient’s response to first-regimen Taxol¹ and carboplatin (TC) chemotherapy. 30% of chemo-naive women do not respond to TC treatment and DNAPrint™ research shows that this problem is largely a function of genetic polymorphism. Women who do not respond to their first regimen do not survive as long as those who do and they are unnecessarily subjected to the pain and difficulty of an ineffective chemotherapy. As an adjunct for the oncologist decision-making process, Ovanome could help improve the standard of first-regimen care for ovarian cancer patients. DNAPrint™ genomics enters into sample collection agreement with bay area oncology group.
BACK TO TOP
STATINOME
STATINOME is a genetic test that measures a patient’s likelihood to develop myalgia as an adverse response to the commonly prescribed Statins Lipitor¹ and Zocor². Myalgia is a Statin side-effect condition characterized by muscle pain, and is a first symptom of the potentially fatal muscle-wasting disease rhabdomyolysis. Though only 1 in every 10,000 patients experiences rhabdomyolysis, about 1% of Lipitor¹ and Zocor² users experience its precursor myalgia. Bayers Statin Baycol³ was recently withdrawn from the market due to an unacceptable fatality rate due to rhabdomyolysis. 2-Zocor is a registered trademark of Merck. 3-Baycol is a registered trademark of Bayer Corporation.
BACK TO TOP
ACENOME
ACENOME is a genetic test for predicting whether a high-blood pressure patient will develop the common cough side-effect caused by treatment with the ACE inhibitors Enalapril and Lisinopril. Respiratory irritation and cough is the most commonly cited reason for discontinuation of ACE inhibitor treatment.
BACK TO TOP
Amerind 1.0
Amerind 1.0 is a genetic test for determining the proportional Northern Native American (i.e. American Indian) and Southern Native American ancestry for individuals of predominantly Native American ancestry.
BACK TO TOP
BC-LOH
BC-LOH is a genetic test we are developing for mapping the relapse risk-status of normal tissue surrounding a breast tumor. The technology could help oncologists determine whether a mastectomy is warranted, and could help save many breast cancer patients from unnecessary mastectomy.
BACK TO TOP
Ondansetron
Through collaboration with the Moffitt Cancer Research Center in Tampa, FL, we are investigating the genetic basis of Ondansetron response. Ondansetron is an anti-emetic for the alleviation of post-operative nausea and vomiting (PONV), but normal doses of the drug do not elicit the desired effect in some patients. A genetic test for predicting Ondansetron response could help reduce extreme discomfort many patients feel after surgery. March 29, 2004 DNAPrint™ genomics, Inc. Forms Joint Research Program with the H. Lee Moffitt Cancer Center and Research Institute
BACK TO TOP
Melphalan/Topotecan
Through collaboration with the Moffitt Cancer Research Center in Tampa, FL, we are investigating the genetic basis of Melphalan/Topotecan (MT) response in multiple myeloma patients. MT is a chemotherapy that prevents the cell division that tumors need to grow but for some patients, normal doses do not elicit the desired effect. A genetic test for predicting MT response could help minimize the likelihood of multiple myeloma relapse. March 29, 2004 DNAPrint™ genomics, Inc. Forms Joint Research Program with the H. Lee Moffitt Cancer Center and Research Institute
BACK TO TOP
Xeleri/Xelox
Through collaboration with the Moffitt Cancer Research Center in Tampa, FL, we are investigating the genetic basis of Xeleri/Xelox response for colon cancer patients. Xeleri/Xelox is a chemotherapy that prevents the cell division that tumors need to grow but for some patients, normal doses do not elicit the desired effect. A genetic test for predicting Xeleri/Xelox response could help minimize the likelihood of colon cancer relapse. March 29, 2004 DNAPrint™ genomics, Inc. Forms Joint Research Program with the H. Lee Moffitt Cancer Center and Research Institute
|
